Background: A risk assessment of in-stent restenosis (ISR) patients is critical for providing adequate treatment. Nevertheless, the prognostic value of high-sensitivity CRP (hs-CRP) levels on ISR has not been consistently demonstrated in clinical studies. In the current meta-analysis, we aim to assess the predictive role of hs-CRP in patients treated with stenting. Methods: We searched PubMed, Web of Science, Embase, and the Cochrane Registry through May 2022. We selected random control trials that compared the effects of different interventions, and that revealed the effects of hs-CRP. Two reviewers independently screened the articles, extracted the data, and assessed the quality of the studies according to the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). The data were pooled using a random-effects meta-analysis. Results: Nine articles were included in the meta-analysis. A total of 1.049 patients received stent implantation, and 185 ISR events were recorded during the 1–12-month follow-up period. Baseline hs-CRP levels were not associated with the prediction of ISR among patients receiving stent implantation. The OR of hs-CRP for ISR was 1.81 (0.92–2.69). In the subgroup analysis, 6–12-month hs-CRP levels, diabetes mellitus (DM), and age ≥60(years)were associated with a higher risk of ISR. Conclusions: This meta-analysis shows that higher levels of baseline hs-CRP are not associated with an increased risk of ISR in stented patients. However, an increased risk of ISR was associated with hs-CRP levels at 6 to 12 months of follow-up, which is higher in studies with diabetes mellitus patients and the elderly.

Background and Hypothesis: Glycemic variability in one fact that explain the differences in cardiovascular outcomes. The short‐term fasting plasma glucose (FPG) variability may have an on major adverse cardiovascular events (MACE) in type 2 diabetes mellitus (T2DM) patients with ST‐segment elevation myocardial infarction (STEMI).Methods: This study retrospectively analyzed T2DM patients who underwent emergent percutaneous coronary intervention (PCI) due to STEMI in Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, between January 2016 and March 2020. All patients underwent at least 5 FPG measurements during the perioperative period. FPG variability score (FPG‐VS) was defined as the percentage of the number of FPG variations > 1 mmol/L between two adjacent FPG measurements. The Cox proportional‐hazards model was used to estimate the relationship between FPG‐VS and MACE. A validation set was utilized to further evaluate the prognostic value of FPG‐VS in a standardized STEMI diabetic diet cohort following PCI intervention.Results: A total of 612 patients were included in the retrospective cohort study. In comparison to the minimum quintile, FPG‐VS > 60% was associated with an increased risk of 30‐day MACE. Moreover, compared to FPG‐VS ≤ 20%, the FPG‐VS > 80% group had a higher risk of MACE (odd ratio [OR] = 4.87, 95% confidence interval [CI]: 2.55−5.28), recurrent angina pectoris (OR = 5.43, 95% CI: 2.27−8.27), nonfatal myocardial infarction (OR = 5.00, 95% CI: 2.47−7.69), heart failure (OR = 3.70, 95% CI: 1.92−5.54), malignant arrhythmia (OR = 4.63, 95% CI: 1.12−6.25) and cardiac death (OR = 1.41, 95% CI: 0.17−1.97). Consistent results were obtained after adjustment for HbA1c, demonstrating the robustness of FPGFPG‐VS. Moreover, the standard diet intervention group had a lower FPG‐VS index as well as a lower incidence of MACE.Conclusion: Higher FPG variability is associated with an increased risk of MACE within 30 days in diabetes patients receiving PCI for STEMI. A standardized diet may improve the prognosis of STEMI patients by reducing the FPG‐VS.

INPLASY2023120009 The Role of Dual Antiplatelet Therapy with Indobufen as Background Therapy in Coronary artery disease： a meta-analysis Keywords: Dual Antiplatelet Therapy; Indobufen ;Coronary art…

Background/Objectives: Dual antiplatelet therapy (DAPT), which combines aspirin with a P2Y12 receptor inhibitor for platelets, is crucial for the prevention of cardiac and systemic ischemic events in patients with coronary artery disease who have undergone revascularization procedures. Although indobufen is suggested as an alternative for individuals who exhibit intolerance to aspirin, the long‐term safety and efficacy of indobufen‐based DAPT treatment for the prevention of cardiac and systemic ischemic events in these patients remain ambiguous. This meta‐analysis seeks to examine the long‐term safety and efficacy of DAPT based on indobufen in the context of revascularization procedures for patients. Methods: A thorough search was performed across PubMed, Embase, the Cochrane Library, Web of Science, ClinicalTrials.gov, and CNKI, covering all records from each database’s inception to October 10, 2024. Included were randomized trials analyzing oral DAPT antiplatelet agents for coronary artery disease patients who received revascularization. Two reviewers independently handled the selection process: screening articles, overview, extracting data, and assessing study quality in accordance with PRISMA guidelines. The pooled data were later subjected to analysis using a random‐effects model meta‐analysis. Results: The final analysis included three randomized controlled trials, which yielded the following findings regarding major adverse cardiovascular and cerebrovascular events (MACCEs): The relative risk (RR) was 1.58 (95% CI, 0.72–3.38); for BARC Type 2, 3, or 5 bleeding events, the RR was 0.35 (95% CI, 0.18–0.67); and for gastrointestinal intolerance events, the RR was 0.06 (95% CI, 0.03–0.18). Conclusions: Indobufen‐based DAPT may potentially increase the risk of ischemic events without compromising safety for revascularization, as its upper RR limit exceeds 1 for MACCEs.

INPLASY202250170 Prognostic Value of High-Sensitive C-Reactive Protein in patients with In-Stent Restenosis： A Meta-Analysis of Clinical Trials Keywords: High-Sensitive C-Reactive Protein; In-Stent…